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OBJECTIVES We sought to assess whether the adjustment of peak oxygen consumption (PkVO2) to lean
body mass would yield a more accurate discriminator of outcomes in the chronic heart failure
population.
BACKGROUND Peak oxygen consumption is traditionally used to risk stratify patients with congestive heart
failure (CHF) and to time cardiac transplantation. There is, however, considerable variability
in body fat content, which represents metabolically inactive mass.
METHODS In 225 consecutive patients with CHF, the percentage of body fat was determined by the sum
of skinfolds technique. All underwent CPX using a ramping treadmill protocol. Mean
follow-up duration was 18.9 6 11.3 months.
RESULTS There were 14 cardiovascular deaths and 15 transplants. Peak oxygen consumption lean, both
as a continuous variable and using a cutoff of #19 ml/kg/min, was a better predictor of
outcome than unadjusted PkVO2 (p 5 0.003 vs. 0.027 for the continuous variables and p 5
0.0006 vs. 0.055 for #19 ml/kg/min and #14 ml/kg/min unadjusted body weight,
respectively). Using partial correlation index R statistics, the Cox model using PkVO2 lean
#19 ml/kg/min, in addition to age and etiology of CHF as covariates, yielded the strongest
predictive relationship to the combined end point (chi-square value 24.32). Especially in the
obese patients and in women, there was considerably better correlation of PkVO2 lean with
outcome than the unadjusted PkVO2.
CONCLUSIONS The adjustment of PkVO2 to lean body mass increases the prognostic value of cardiopul-
monary stress testing in the evaluation of patients with chronic heart failure. The use of
,19 ml O2/kg of lean body mass/min as a cutoff in PkVO2 should be used for timing
transplantation, particularly in women and the obese. (J Am Coll Cardiol 2000;36:2126–31)
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As the treatment armamentarium in heart failure be-
comes increasingly complex and diverse, clinical strate-
gies, based on functional capacity, to effectively triage
patients with systolic heart failure into distinct prognostic
subgroups are necessary. Peak oxygen uptake (PkVO2)
measured during exercise not only allows accurate evalu-
ation of exercise capacity, but also has been shown to be
a strong independent predictor of survival in chronic
heart failure (1,2). Initially, Mancini and colleagues (3)
demonstrated that a PkVO2 of .14 ml/kg/min identified
a low-risk cohort of patients. The survival of these
patients was not improved by transplantation, and Man-
cini et al. (3) recommended that a PkVO2 of 14 ml/kg/
min be used as a discriminator for those being considered
for transplantation. Subsequently, investigators have
sought further refinements in this particular criterion,
and other gas exchange variables have been evaluated for
their predictive strengths, including percent predicted
PkVO2 (4,5), peak systolic blood pressure (6) and venti-
lation/carbon dioxide production ratio (7). The investi-
gators demonstrated variability with regard to each pa-
rameter’s predictive strength.
Peak oxygen uptake is traditionally corrected for total
body weight and is reported in milliliters per kilogram of
body weight per minute (ml/kg/min). Body fat, however,
can represent a significant portion of total body weight,
and it consumes essentially no oxygen. Moreover, con-
siderable variability in body composition is present across
populations, including those manifesting heart failure.
We reasoned that PkVO2 corrected for lean body mass
(LBM) would reflect a more accurate picture of cardio-
pulmonary function during exercise and could serve as a
better discriminator of clinical outcome than standard
weight and relative predictive measures. The purpose of
our investigation was threefold: first, to assess the pre-
dictive strength of PkVO2 adjusted to LBM (PkVO2
lean) in determining clinical outcomes in patients with
moderate to severe chronic systolic heart failure; second,
to stratify patients with systolic heart failure into high-
and low-risk groups based on the value of PkVO2 lean
and third, to define specific subpopulations, particularly
women and the obese, that may merit mandatory appli-
cation of this prognostic criterion.
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METHODS
Patients. We prospectively studied 225 consecutive ambu-
latory patients with chronic systolic heart failure who were
referred for cardiopulmonary exercise testing as part of a
comprehensive heart failure evaluation between November
1995 and December 1998. The average age of the 45
women and 180 men was 54 6 12 years (range 19 to 85
years). All patients had heart failure for at least six months
and were on stable doses of their medications with no
exacerbation of symptoms or need for intravenous inotropic
support for a duration of four weeks before assessment.
Patients were excluded if they exhibited severe peripheral
vascular disease, low threshold angina or had orthopedic
limitations preventing them from exercise testing. The
baseline demographic and clinical characteristics are shown
in Table 1.
Cardiopulmonary exercise testing. The research proto-
col was approved by the institutional review board, and
informed consent was obtained from all patients who were
then exercised maximally on a treadmill using an individu-
ally tailored ramping protocol designed to yield a test
duration of between 8 and 12 min. Patients were encour-
aged to exercise until symptoms of chest discomfort or
dyspnea were intolerable. Breath-to-breath online gas anal-
ysis was performed using a MedGraphics CPXID metabolic
cart (St. Paul, Minnesota). Incremental data including
minute ventilation, oxygen consumption (VO2) and carbon
dioxide production were collected every 15 s.
Body fat assessment. The percentage of body fat was
determined by the skinfold technique using the average of
three skinfolds (thigh, chest and abdomen in men; thigh,
triceps and suprailium in women) (8). Skinfolds were
measured in the fasting state in the morning before exercise
by a single observer.
Cardiopulmonary parameters. From the above data,
maximal VO2, anaerobic threshold (AT) and respiratory
exchange ratio were calculated as previously described (9).
Peak VO2 was determined as the highest oxygen uptake
observed during the test. Anaerobic threshold was defined
as the VO2 at which expired carbon dioxide increased
nonlinearly relative to VO2 (V-slope method). Predicted
maximum VO2 was determined using the revised regression
equations of Wasserman et al. (9), which take gender, age
and obesity into consideration. Peak VO2 lean was defined
as the VO2 corrected for LBM [LBM 5 actual body
weight 3 (12 % body fat/100)] in milliliters of oxygen per
kilogram of LBM per minute.
Outcome measures. All patients were followed at the
Ochsner Cardiomyopathy and Heart Transplantation Cen-
ter, and outcome data were prospectively collected from
medical records or interviews. The principal outcomes
assessed included the composite end point of death due to
cardiovascular causes and need for urgent cardiac transplan-
tation. Listing for transplant was done by committee con-
sensus based primarily on PkVO2 but also in concert with
other clinical, metabolic and hemodynamic variables.
Statistical analysis. Continuous variables are expressed
as mean 6 1 standard deviation. Discrete variables are
shown as percentages. Categorical variables were compared
using the likelihood ratio chi-square test. With continuous
variables, group means were compared with the unpaired
Student t test or Wilcoxon rank sum test if the variable did
not hold the normality assumption. Diagnostic test analysis
was performed to calculate sensitivity, specificity, likelihood
ratios, positive predictive values and negative predictive
values for PkVO2 using a cut-off of 14 ml/kg/min and
PkVO2 lean using a cutoff of 19 ml/kg/min (Table 2).
Abbreviations and Acronyms
AT 5 Anaerobic Threshold
CHF 5 Congestive Heart Failure
LBM 5 Lean Body Mass
MVV 5 Maximal Voluntary Ventilation
NPP 5 Negative Predictive Value
NYHA 5 New York Heart Association
PkVO2 5 peak oxygen consumption
PPV 5 Positive Predictive Value
TX 5 Urgent Transplantation
VE 5 Maximal Minute Ventilation
VO2 5 Oxygen Consumption
Table 1. Clinical and Exercise Characteristics of the Study
Population (n 5 225)
Clinical Characteristics Data (Mean 6 SD)
Age (yrs) 54.3 6 12.2
Gender, male (%) 183 (80%)
Weight (kg) 89 6 19
Body mass index (kg/m2) 28.9 6 5.4
Obese ($30 kg/m2) 83 (37%)
% fat 25.9 6 7.6
Lean weight (kg) 67.3 6 14.1
Etiology: ischemic 132 (58.1%)
Nonischemic 93 (41.9%)
Left ventricular ejection fraction, % 23 6 13
NYHA class 2.4 6 0.6
Medications, %
Lanoxin 83%
Diuretics 82%
Angiotension-converting enzyme
inhibitors or angiotensin-
blockers
95%
Beta-blockers 31%
Exercise Characteristics
Resting heart rate, beats/min 81 6 16
Peak heart rate, beats/min 126 6 24
Rest systolic pressure, mm Hg 129 6 19
Peak systolic pressure, mm Hg 147 6 29
Anaerobic threshold, ml/kg/min 12.7 6 4.1
PkVO2, ml/kg/min 16 6 5.9
PkVO2 lean, ml/kg/min 21.2 6 7.4
% of predicted PkVO2 69.2 6 22.6
NYHA 5 New York Heart Association; PkVO2 5 peak oxygen consumption; SD 5
standard deviation.
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19 ml/kg/min was determined by using receiver operator
characteristic curve analysis. We also compared the two tests
evaluated against the same “gold standard” in the same
sample with Kappa indexes and using the area under the
curve.
Bivariate analysis was performed with PkVO2 as: 1)
continuous absolute variable, 2) adjusted to LBM and 3) as
percent of predicted. Cutoffs of 14 ml/kg/min, 50% pre-
dicted PkVO2 and 19 ml/kg/min of PkVO2 lean (derived
from the median tendency of the data) were also used to
categorize the results.
Cox proportional hazard regression analysis was per-
formed to determine the independent predictors of event-
free survival. Variables showing significance at an alpha level
of 0.15 in bivariate analysis and age were included. Six
models were then built using the PkVO2 variables and other
variables showing at least marginal predictive value (p ,
0.15) on stepwise analysis.
Partial correlation index R statistics were used to compare
the power of the individual variables within and between the
six models. The assumption of proportional hazard was also
assessed graphically. The results are shown as relative (or
hazard) risks and their respective 95% confidence intervals.
All tests were two-sided, and p values ,5% were considered
significant.
Survival curves were also constructed using the Kaplan-
Meier product limit method and were compared with the
log-rank test. Analysis of covariance was also performed to
assess the differences in clinical and PkVO2 parameters as
well as in outcomes across the gender line and between
obese and nonobese patients.
All calculations were performed using JMP software
version 3.2.2 (SAS Institute, Inc., Cary, North Carolina)
and PEPI version 3.00 (USD, Inc., Stone Mountain,
Georgia).
RESULTS
Study population. Table 1 depicts the baseline clinical and
exercise characteristics of the study population. The median
follow-up duration was 19.5 months (range 2 to 40.4
months and mean 18.9 6 11.3 months) during which time
there were 29 cardiac events (14 cardiovascular deaths and
15 urgent transplants). Only two patients were lost to
follow-up.
Table 2 demonstrates the superior diagnostic character-
istics of the proposed lean PkVO2 cutoff of 19 ml/kg/min.
The clinical and exercise characteristics of the event-free
survivors and patients who reached the combined end point
of cardiac death or transplant are shown in Tables 3 and 4.
The etiology of cardiomyopathy and percent body fat
were significantly different between event-free survivors and
those who reached the combined end point. The lean body
weight, maximum minute ventilation and maximum volun-
tary ventilation were comparable between both groups and
so were heart rate and systolic blood pressure at rest, AT and
peak exercise.
Cardiopulmonary predictors. Anaerobic threshold (p 5
0.03), percent of predicted PkVO2 (p 5 0.0016) and
unadjusted and lean PkVO2 (p 5 0.02 and 0.003, respec-
tively) were significant predictors of cardiac mortality and
transplantation. Unadjusted and lean PkVO2 were also
Table 2. Diagnostic Tests Analysis
Precision Estimates
PkVO2 < 14
(ml/min/kg)
PkVO2 Lean <19
(ml/min/kg) p Value
Sensitivity 63.6% 72.3%
Specificity 56% 59.3%
Likelihood ratio:
For positive test 1.45 (1.01 to 2.08) 1.78 (1.30 to 2.45)
For negative test 0.65 (0.37 to 1.15) 0.46 (0.23 to 0.92)
PPV 16.9% 20.1%
NPP 91.7% 93.9%
Kappa 0.09 0.15 0.04
AUC 0.58 0.67 0.0001
AUC 5 area under the curve; NPP 5 negative predictive value; PkVO2 5 peak oxygen consumption; PPV 5 positive predictive
value.
Table 3. Univariate Analysis of Clinical Characteristics Between
Survivors and Those Reaching the Combined End Points
Clinical characteristics
Survivors
(n 5 196)
Death/TX
(n 5 29) p Value
Age (yrs) 54 6 12 54 6 13.3 NS
Weight (kg) 90 6 18.8 85.6 6 20.7 NS
Body mass index (kg/m2) 29.1 6 5.4 27.7 6 5 NS
% obese 52.6 37.9 NS
% fat 26.4 6 7.6 22.6 6 6.7 0.018
Lean body weight (kg) 67.3 6 13.9 66.6 6 15.4 NS
Gender: female 38 (19.6%) 4 (13.8%) NS
male 156 (80.4%) 25 (86.2%)
CHF etiology 0.0015
ischemic 72 (37.7%) 20 (69%)
nonischemic 119 (62.3%) 9 (31%)
NYHA classification I 19 1 0.029
II 84 8
III 85 20
Mean NYHA class, unit 2.3 6 0.6 2.7 6 0.5 0.001
Left ventricular ejection
fraction, %
25 6 13 20 6 9 NS
Left ventricular end-
diastolic diameter,
cm
6.0 6 1.2 6.4 6 0.8 0.07
CHF 5 congestive heart failure; NYHA 5 New York Heart Association; TX 5
urgent transplantation.
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significantly predictive of cardiac mortality alone (p 5 0.04
and 0.035, respectively). Whereas categorical cutoffs of a
percentage of predicted VO2 #50 and PkVO2 #14 ml/kg/
min showed a trend towards significance in our population,
a PkVO2 lean #19 ml/kg/min correlated best with the
combined end point (p 5 0.0006).
In partial correlation index R analysis the use of PkVO2
lean #19 ml/kg/min yielded the strongest predictive model
for the combined end point (Table 5). Both models using
the adjusted maximal VO2 were more predictive than the
unadjusted models. It is noteworthy that the percent of
predicted peak VO2 as a continuous variable resulted in a
stronger model than a cutoff of ,50% of predicted. We then
categorized our population using both the conventional and
the proposed body fat adjusted cutoffs and analyzed on a
univariate basis the clinical, exercise and outcome data of
the resulting groups. There was a more significant difference
in outcomes when the lean PkVO2 cutoff was used.
Survival analysis. Figure 1 shows the Kaplan-Meier sur-
vival curves using a PkVO2 of 14 ml/kg/min and a PkVO2
lean of 19 ml/kg/min to categorize our study population. At
12 months patients with a PkVO2 lean #19 ml/kg/min had
a survival of 80% as compared with 98% for those whose
values were .19 ml/kg/min.
Discordant variable analysis. Further examination of pa-
tients demonstrating discordant cardiopulmonary variables
(for example, PkVO2 .14 ml/kg/min but PkVO2 lean
#19 ml/kg/min or vice versa) found 18 patients that showed
discordant PkVO2 levels. None of the eight patients that
had a PkVO2 #14 ml/kg/min and an adjusted PkVO2
.19 ml/kg/min reached any of the outcomes. It is note-
worthy that this group was composed of mostly obese (6 of
8) women (5 of 8). On the other hand, of the 10 patients
with the opposite discordance (PkVO2 .14 ml/kg/min but
PkVO2 lean #19 ml/kg/min), 4 had major events, including
2 who required urgent cardiac transplantation and 2 who
died of progressive heart failure. This analysis exemplifies
the incremental prognostic value provided by body fat
adjusted PkVO2 when the “standard” clinical cutoffs of
PkVO2 fail to segregate risk.
Subgroup analysis: women and obesity. Women (n 5 45,
20% of the whole group) were more likely to have nonisch-
emic disease (73% vs. 56%, p 5 0.02), a lower total body
weight (mean of 78.6 6 20.7 vs. 92.2 6 19.2 kg, p ,
0.0001) but a higher percentage of body fat (34.1 6 8.3% vs.
24 6 6%, p , 0.0001) as compared with men. They
achieved a lower unadjusted PkVO2 level (13.5 6 5.2 vs.
16.2 6 5.8 ml/kg/min, p 5 0.0002) but no statistical
difference when PkVO2 lean was used (18.8 6 7.6 vs.
20.4 6 7.5 ml/kg/min, p 5 0.11). There was no difference
in outcome between both groups (13.2% of women died or
underwent transplantation compared with 18.8% of men,
p 5 0.4) and, therefore, body fat adjusted VO2 (lean) was a
Figure 1. Kaplan-Meier survival curves using both PkVO2 of 14 ml/kg/
min and PkVO2 lean of 19 ml/kg/min as cutoffs showing a stronger
prognostic value to the fat-adjusted PkVO2 by log-rank testing. PkVO2 5
peak oxygen consumption; PkVO2 lean 5 peak oxygen consumption
adjusted to lean body mass; VO2 5 oxygen consumption.
Table 4. Univariate Analysis of Exercise Characteristics Between
Survivors and Those Reaching the Combined End Point
Exercise Characteristics
Survivors
(n 5 196)
Death/TX
(n 5 29)
p
Value
Maximal voluntary ventilation,
L/min
97.3 6 38.9 94.9 6 35.2 NS
Maximum minute ventilation,
L/min
50.8 6 18.2 54.6 6 34.7 NS
Rest heart rate (beats/min) 86 80 NS
Peak heart rate (beats/min) 130 6 25 124 6 23 NS
Rest systolic pressure (mm Hg) 130 6 19 127 6 19 NS
Peak systolic pressure (mm Hg) 151 6 30 143 6 29 NS
Anaerobic threshold
(ml/kg/min)
12.9 6 4.1 10.9 6 3.1 0.03
PkVO2 (ml/kg/min) 16.3 6 6 13.8 6 4.4 0.027
PkVO2 lean (ml/kg/min) 21.7 6 7.6 17.5 6 5 0.003
% predicted VO2 70.9 6 23.1 57 6 14.4 0.0016
PkVO2 #14 ml/kg/min,
number (%)
77 (39.7%) 17 (58.6%) 0.055
% pred. VO2 #50, number (%) 37 (19.1%) 10 (34.5%) 0.07
PkVO2 lean #19 ml/kg/min,
number (%)
75 (38.7%) 21 (72.4%) 0.0006
PkVO2 5 peak oxygen consumption.
Table 5. Cox Proportional Hazard Model Comparisons, Including Age and Etiology
of Cardiomyopathy
Models Chi-square RR 95% CI p Value
PkVO2 lean #19 ml/kg/min 24.32 0.24 0.1–0.58 ,0.0001
% predicted PkVO2 21.53 0.97 0.95–0.99 ,0.0001
PkVO2 lean 20.53 0.91 0.85–0.98 0.0001
PkVO2 17.17 0.91 0.84–1 0.0007
PkVO2 #14 ml/kg/min 16.38 2.22 1.02–4.8 0.0009
% predicted PkVO2 ,50 15.65 0.47 0.22–1.03 0.0013
CI 5 confidence interval; PkVO2 5 peak oxygen consumption; RR 5 relative risk.
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better discriminator of clinical outcome than unadjusted
values.
Obese patients (body mass index $ 30 kg/m2), which
consisted of 83 patients or 37% of the cohort, showed
statistically lower AT (11.5 6 3.5 vs. 12.7 6 4.2 ml/kg/min,
p 5 0.03) and unadjusted PkVO2 levels (14.4 6 4.7 vs.
16.5 6 6.1 ml/kg/min, p 5 0.04) yet similar PkVO2 lean
levels (19.3 6 6.7 vs. 20.5 6 7.9 ml/kg/min, p 5 0.2).
There was no statistical difference in outcome, with 10% of
obese patients reaching one of the end points compared
with 17.8% of the nonobese patients (p 5 0.1), indicating
the more accurate stratification of prognosis provided by
body fat adjusted VO2.
On the other hand, lean men accounted for 48% (n 5
108) of the study cohort. In this group, PkVO2 lean was still
a slightly better predictor of the risk of major cardiovascular
events than unadjusted PkVO2 (p 5 0.03 and 0.08, respec-
tively).
DISCUSSION
Study findings. The results of our prospective investigation
demonstrate that, in ambulatory patients with chronic
systolic heart failure, the simple adjustment of PkVO2 to
lean body weight provides much greater prognostic strength
than the traditionally reported standard of PkVO2 per
kilogram of total body weight. Furthermore, a value of
PkVO2 lean of #19 ml/kg/min provides the best discrim-
inator of adverse outcome, yielding a survival of 80% and
68% at 12 and 36 months, respectively. Additionally, we
identified women and obese patient subgroups with a higher
percent body fat in which using PkVO2 lean may be
particularly beneficial compared with unadjusted PkVO2
determinations.
Aerobic capacity and prognosis. Peak oxygen uptake,
normalized for total body weight, is a powerful short-term
prognostic parameter in patients with chronic heart
failure and has been used successfully to guide candidate
selection for heart transplantation. In the Veterans Admin-
istration Heart Failure Trials (VHeFT I and II), a PkVO2
,14.5 ml/kg/min predicted an increased mortality from
11.6% to 18.4% in patients with ejection fractions ,28%
when compared with values .14.5 ml/kg/min (10). Man-
cini et al. (3) reported in a study of 114 patients with severe
heart failure that 94% of patients with a weight adjusted
PkVO2 higher than 14 ml/kg/min were alive at 1 year, and
84% were alive at 2 years. This good prognosis allowed the
safe deferral of heart transplantation in the near term in
those with PkVO2 values .14 ml/kg/min. Aaronson and
Mancini (3,11), and then our group, found that the percent
of predicted maximum VO2 was a better prognosticator
than PkVO2 in women with chronic heart failure, a popu-
lation with traditionally higher values of percent body fat.
The percent of predicted PkVO2 has also been suggested as
an additional prognostic variable, particularly for patients
who have PkVO2 ,14 ml/kg/min (5,12). The discrepancy
across the gender line as well as the known contribution of
body fat changes in VO2 led us to examine the effect of lean
weight adjusted PkVO2 on the overall prognostic power of
peak aerobic capacity.
Rationale of body fat adjusted PkVO2. Body fat repre-
sents metabolically inactive mass, and, as a percentage of
total body weight, is highly variable across populations. The
observed increase in body fat that occurs with aging has
been shown to contribute to the age-related decline in
PkVO2 reported in men and women (13). Drinkwater et al.
(14) found that, despite a gradual increase in body weight
over 2 decades, the PkVO2 of a group of very active women
did not decline (14). In a study of 56 healthy subjects,
Buskirk et al. (15) found that LBM correlated better with
peak VO2 than did total body weight. We previously
studied the impact of reducing body fat during exercise
training on the observed improvement in PkVO2 after
aerobic conditioning and found that the decrease in body fat
overestimated the true increase in peak aerobic capacity
(16). We suggested the use of a “corrected” peak VO2
adjusted for LBM in order to assess the true effect of
exercise conditioning, especially in subgroups with a higher
percent body fat (17). Using the sum of three skinfold
thicknesses as described by Jackson and Pollock (18,19), the
body density can be calculated and the percent of body fat
derived (8,18–20). This method was chosen from a large
number of other well-validated methods because its appli-
cation can be easily adopted by the exercise laboratory and
the requirement of fewer measurements while maintaining a
high level of accuracy (21–23).
Prognostic utility. We compared the proposed PkVO2
lean to the established unadjusted value to determine their
respective prognostic strengths for the outcomes of death
and urgent transplantation. By multivariate analysis using
the combined end point of cardiac death or urgent trans-
plantation, we have demonstrated that PkVO2 adjusted to
LBM refines the weight adjusted peak aerobic capacity and
provides a variable with greater prognostic discrimination
than previously described, particularly in women and the
obese. Thus, using a PkVO2 lean .19 ml/kg/min as a
prognostic threshold, rather than the traditional cutoff point
of PkVO2 of 14 ml/kg/min, provides a more comprehensive
and accurate prognostic variable across the entire heteroge-
neous population of chronic heart failure. Furthermore,
PkVO2 lean adjusted for body fat, therefore, allows deter-
mination of prognosis in the specific subpopulations of
women and the obese with greater predictive confidence.
Study limitations. Although the “gold standard” method
for body fat assessment (underwater weighing) was not
employed, the method of sum of several skinfold thicknesses
proposed by Jackson and Pollock (16) was chosen. Several
studies have shown that anthropometric techniques, in
particular those using the skinfold fat thickness, provide
excellent correlation with underwater weighing (8). The
generalized equations used have been validated and have
been widely used because of the smaller number of mea-
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surements required. It is noteworthy, however, that this
estimate is less accurate at the extremes of age and weight
(8).
In this study, as in others assessing the prognostic value of
cardiopulmonary stress testing in heart failure, there is
unavoidable referral bias towards transplantation after car-
diopulmonary assessment. This may have been reduced, but
not abolished, by the use of urgent transplantation rather
than a listing as status I (4,5) as a cardiac end point.
Conclusions. As Buskirk wrote in 1957, “It is concluded
that when VO2 is used to examine the performance of the
respiratory-cardiovascular system, the values should be ex-
pressed as VO2 per kilogram of fat-free weight” (15). This
investigation confirms the incremental prognostic predictive
capability of adjustment of the PkVO2 achieved to lean
body weight in ambulatory chronic systolic heart failure. It
also provides evidence that this cardiopulmonary exercise
parameter offers the best risk stratification across the heter-
ogeneous systolic heart failure cohort including women and
the obese.
Reprint requests and correspondence: Dr. Richard V. Milani,
Department of Cardiology, Ochsner Medical Institutions, 1514
Jefferson Highway, New Orleans, Louisiana 70121. E-mail:
rmilani@ochsner.org.
REFERENCES
1. Mehra MR, Lavie CJ, Milani RV. Predicting prognosis in advanced
heart failure: use of exercise indices. Chest 1996;110:310–2.
2. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation
of chronic cardiac failure. Am J Cardiol 1985;55:22A–31A.
3. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Jr.,
Wilson JR. Value of peak exercise oxygen consumption for optimal
timing of cardiac transplantation in ambulatory patients with heart
failure. Circulation 1991;83:778–86.
4. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of
cardiopulmonary exercise testing using percent achieved of predicted
peak oxygen uptake for patients with ischemic and dilated cardiomy-
opathy. J Am Coll Cardiol 1996;27:345–52.
5. Osada N, Chaitman BR, Miller LW, et al. Cardiopulmonary exercise
testing identifies low-risk patients with heart failure and severely
impaired exercise capacity considered for heart transplantation. J Am
Coll Cardiol 1998;31:577–82.
6. Myers J, Gullestad L, Vagelos R, et al. Clinical, hemodynamic and
cardiopulmonary exercise test determinants of survival in patients
referred for evaluation of heart failure. Ann Intern Med 1998;129:
286–93.
7. Milani RV, Mehra MR, Reddy TK, Lavie CJ, Ventura HO. Venti-
lation/carbon dioxide production ratio in early exercise predicts poor
functional capacity in congestive heart failure. Heart 1996;76:393–6.
8. Jackson AS, Pollock ML. Practical assessment of body composition.
Physician Sports Med 1985;13:76–90.
9. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ. Principles
of Exercise Testing and Interpretation. Philadelphia: Lea & Febiger,
1999.
10. Cohn J, Johnson G, Shabetai R, et al. Ejection fraction, peak exercise
oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and
plasma norepinephrine as determinants of prognosis in heart failure.
Circulation 1993;87 Suppl:VI5–16.
11. Richards DR, Mehra MR, Ventura HO, et al. Usefulness of peak
oxygen consumption in predicting outcome of heart failure in women
versus men. Am J Cardiol 1997;80:1236–8.
12. Aaronson KD, Mancini DM. Is percentage of predicted maximal
exercise oxygen consumption a better predictor of survival than peak
exercise oxygen consumption for patients with severe heart failure?
J Heart Lung Transplant 1995;14:981–9.
13. Toth MJ, Gardner AW, Ades PA, Poehlman ET. Contribution of
body composition and physical activity to age-related decline in peak
VO2 in men and women. J. Appl Physiol 1994;77:647–52.
14. Drinkwater BL, Horvarth SM, Wells CL. Aerobic power of females,
ages 10 to 68. J Gerontol 1975;30:385–94.
15. Buskirk E, Taylor HL. Maximal oxygen intake and its relation to body
composition, with special reference to chronic physical activity and
obesity. J Appl Physiol 1957;11:72–8.
16. Milani RV, Lavie CJ. The effects of body composition changes to
observed improvements in cardiopulmonary parameters after exercise
training with cardiac rehabilitation. Chest 1998;113:599–601.
17. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise
training programs on peak aerobic capacity and work efficiency in
obese patients with coronary artery disease. Am J Cardiol 1999;83:
1477–80.
18. Jackson AS, Pollock ML. Generalized equations for predicting body
density of men. Br J Nutr 1978;40:497–504.
19. Pollock ML, Schmidt DH, Jackson AS. Measurement of cardiorespi-
ratory fitness and body composition in the clinical setting. Compr
Ther 1980;6:12–27.
20. Brozeck J, Grande F, Anderson JT, Keys A. densitometric analysis of
body composition and revision of some quantitative assumptions. Ann
NY Acad Sci 1963;110:113–40.
21. Thorland WG, Johnson GO, Tharp GD, Fagot TG, Hammer RW.
Validity of anthropometric equations for the estimation of body
density in adolescent athletes. Med Sci Sports Exerc 1984;16:77–81.
22. Housh TJ, Johnson GO, Housh DJ, Eckerson JM, Stout JR. Validity
of skinfold estimates of percent fat in high school female gymnasts.
Med Sci Sports Exerc 1996;28:1331–5.
23. Stout JR, Eckerson JM, Housh TJ, Johnson GO, Betts NM. Validity
of percent body fat estimations in males. Med Sci Sports Exerc
1994;26:632–6.
2131JACC Vol. 36, No. 7, 2000 Osman et al.
December 2000:2126–31 Body Fat Adjusted PkVO2 in CHF
